Indonesia Chronic Cough Therapeutics Market Analysis

Indonesia Chronic Cough Therapeutics Market Executive Summary

Indonesia's Chronic Cough Therapeutics Market was valued at $38 Mn in 2022 and is estimated to reach $70 Mn in 2030, exhibiting a CAGR of 8.1% during the forecast period.

Chronic cough is a persistent cough lasting more than eight weeks, distinguishing it from acute coughs associated with short-term conditions. Unlike short-term coughs often linked to infections, chronic cough can indicate a more enduring underlying health problem. Respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), gastroesophageal reflux disease (GERD), postnasal drip, and certain medications commonly cause chronic cough. Identifying and addressing the root cause through a thorough medical assessment is essential for effective management. Chronic cough significantly impacts the quality of life, often requiring a comprehensive, multidisciplinary approach involving healthcare professionals such as pulmonologists, gastroenterologists, or ear, nose, and throat (ENT) specialists.

In Indonesia, persistent cough is a serious health issue that is impacted by a variety of factors, including smoking prevalence, air quality, and environmental contaminants. Chronic coughs that last longer than 8 weeks are common and affect people's quality of life, productivity at work, and access to healthcare resources. Due to regional differences in access to healthcare services, efforts must be made to improve accessibility, particularly in rural areas, to facilitate early diagnosis and management. The perception and management of chronic cough are influenced by cultural beliefs and practices, underscoring the significance of comprehending cultural subtleties in the provision of healthcare. To promote healthy lifestyles, lessen exposure to environmental triggers, and encourage prompt medical intervention, public awareness campaigns, and educational programs are essential. Collaborations in ongoing studies are necessary to identify specific reasons and create customized remedies for the complex character of chronic cough in the Indonesian population.

Akari Therapeutics has taken a significant step in addressing chronic cough in China by partnering with a Chinese Contract Research Organization (CRO) to commence a Phase 2a clinical trial for ATS-2893, a nasal spray. This collaboration emphasizes the commitment to exploring innovative solutions for chronic cough management and showcases the collaborative efforts between international pharmaceutical companies and Chinese research entities.

Market Dynamics

Market Growth Drivers

Increasing Prevalence of Chronic Cough: Increasing urbanization and lifestyle changes, such as smoking and exposure to air pollutants, are causing respiratory issues to worsen. The prevalence of chronic cough and its related problems is on the rise. The elderly population, which is more likely to experience long-term health issues, is more vulnerable to ailments like chronic cough.

Prevalence of Smoking: Indonesia has a notable prevalence of smoking, which is a significant contributor to respiratory issues, including chronic cough. Addressing the impact of smoking-related cough creates a demand for therapeutic interventions, ranging from smoking cessation programs to targeted cough treatments.

Rising Awareness and Diagnosis: Growing awareness among both healthcare professionals and the general population regarding the impact of chronic cough on quality of life is leading to increased diagnosis. As awareness improves, more individuals seek medical attention for their chronic cough symptoms, driving the demand for therapeutic interventions.

Market Restraints

Regulatory Hurdles: Stringent regulatory requirements and approval processes in Indonesia can present difficulties for pharmaceutical companies aiming to introduce new treatments for chronic cough to the market. Navigating complex regulatory frameworks may result in delays in product approvals and market entry.

Healthcare Infrastructure Challenges: In certain regions of Indonesia, the healthcare infrastructure may have limitations, including access to specialized diagnostic facilities and healthcare professionals. This can impact the diagnosis and management of chronic cough, hindering the adoption of advanced therapeutics.

Affordability and Reimbursement Issues: Economic considerations and divergent extents of insurance coverage might impact the accessibility of chronic cough treatments for certain population segments. Constrained reimbursement alternatives could potentially dissuade individuals from initiating or sustaining their treatment.

Healthcare Policies and Regulatory Landscape

In Indonesia, the collaboration between the Ministry of Health (Kemenkes) and the National Agency of Drug and Food Control (Badan Pengawas Obat dan Makanan-BPOM) is integral to regulating the pharmaceutical landscape. BPOM plays a crucial role in the approval and supervision of pharmaceutical marketing authorizations, ensuring the quality, safety, and efficacy of products. The Ministry of Health establishes comprehensive healthcare guidelines, influencing the standards adhered to by these medications. The national health insurance program, Jaminan Kesehatan Nasional (JKN), has a significant impact on the accessibility and payment processes for medications used in treating brain cancer. Ongoing efforts to establish health technology assessment mechanisms and enact laws governing clinical trials and research also affect the review and approval procedures within the pharmaceutical regulatory framework.

Competitive Landscape

Key Players

• Kalbe Farma
• Sanofi
• Bristol-Myers Squibb
• PT Merck Sharp & Dohme
• PT Pfizer
• AstraZeneca
• Boehringer Ingelheim
• Chiesi
• Novartis
• GlaxoSmithKline